ASACOLON Tablets Gastro-Resistant 400 Milligram

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

MESALAZINE

Available from:

Tillotts Pharma Limited

Dosage:

400 Milligram

Pharmaceutical form:

Tablets Gastro-Resistant

Authorization date:

2005-01-07

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Asacolon 400mg Gastro-Resistant Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gastro-resistant tablet contains: Mesalazine 400mg.
Excipients: also contains 76.4 mg of lactose monohydrate, _see section 4.4_. for further details.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Gastro-resistant Tablet.
The tablets are reddish to brownish and oblong-shaped.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the treatment of mild acute ulcerative colitis. For the maintenance of remission of ulcerative colitis.
For the maintenance of surgically-induced remission of Crohn’s Disease.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Oral administration.
The tablets should be swallowed whole with a glass of water one hour before food intake.
They must not be chewed, crushed or broken before swallowing. If one or more doses have been missed, the next dose
is to be taken as usual.
Adults:
_Ulcerative colitis:_
Induction of remission:
2.4 g (6 tablets) per day in divided doses. If required the dose may be increased to 4 g (10 tablets) daily.
The dosage can be adjusted in accordance with the response to the treatment.
Maintenance of remission:
1.2 to 2.4 g (3 to 6 tablets) per day in divided doses.
_Crohn’s disease:_
Maintenance of remission:
2.4 g (6 tablets) per day in divided doses.
The elderly
As for adults above unless renal function is impaired (see 4.3 and 4.4). No studies have been carried out in the elderly.
Children
There is no dose recommendation for children (see 4.3 and 4.4).
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 07/11/2011_
_CRN 2103419_
_page number: 1_
4.3 CONTRAINDICATIONS
Asacolon
                                
                                Read the complete document
                                
                            

Search alerts related to this product